Kymera Therapeutics, Inc. (KYMR) — Financial statements
Income statement, balance sheet, and cash flow for Kymera Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 39↓16.7% | 47↓40.1% | 79↑67.8% | 47↓35.7% | 73 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 39↓16.7% | 47↓40.1% | 79↑67.8% | 47↓35.7% | 73 | |
| Operating Expenses | ||||||
| R&D Expenses | 317↑31.8% | 240↑27.1% | 189↑15.1% | 164↑19.9% | 137 | |
| General & Administrative Expenses | 68↑7.3% | 64↑15.4% | 55↑25.6% | 44↑20.6% | 36 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 68↑7.3% | 64↑15.4% | 55↑25.6% | 44↑20.6% | 36 | |
| Other Expenses | 4↓22.8% | 5 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 389↑25.9% | 309↑26.5% | 244↑17.3% | 208↑20.0% | 173 | |
| Total Costs & Expenses | 389↑25.9% | 309↑26.5% | 244↑17.3% | 208↑20.0% | 173 | |
| Operating Results | ||||||
| Operating Income | -349↓33.5% | -262↓58.1% | -166↓2.7% | -161↓60.4% | -101 | |
| Depreciation & Amortization | 8↑12.7% | 7↑106.8% | 4↑19.8% | 3↑24.2% | 2 | |
| EBITDA | -303↓40.2% | -216↓51.0% | -143↑5.6% | -152↓55.3% | -98 | |
| EBIT | -311↓39.2% | -224↓52.4% | -147↑5.1% | -155↓54.6% | -100 | |
| Interest & Other Income | ||||||
| Net Interest Income | 38↑0.0% | 38↑103.5% | 19↑188.0% | 6↑1960.1% | 0.31 | |
| Interest Income | 38↑0.0% | 38↑102.7% | 19↑183.3% | 7↑1257.4% | 0.49 | |
| Interest Expense | 0.25↑0.0% | 0.25↑27.0% | 0.20↑11.4% | 0.18↑0.6% | 0.18 | |
| Non-Operating Income | -38↑0.0% | -38↓102.7% | -19↓183.3% | -7↓1257.4% | -0.49 | |
| Other Income / Expenses | 38↑0.0% | 38↑103.5% | 19↑188.0% | 6↑1960.1% | 0.31 | |
| Income Before Tax | -312↓39.2% | -224↓52.3% | -147↑5.1% | -155↓54.5% | -100 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -312↓39.2% | -224↓52.3% | -147↑5.1% | -155↓54.5% | -100 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -311↓39.1% | -224↓52.3% | -147↑5.1% | -155↓54.5% | -100 | |
| Bottom-Line Net Income | -311↓39.1% | -224↓52.3% | -147↑5.1% | -155↓54.5% | -100 | |
| EPS (Basic) | -3.69↓23.8% | -2.98↓18.3% | -2.52↑12.2% | -2.87↓37.3% | -2.09 | |
| EPS (Diluted) | -3.69↓23.8% | -2.98↓18.3% | -2.52↑12.2% | -2.87↓37.3% | -2.09 | |
| Weighted Average Shares | 84↑12.5% | 75↑28.6% | 58↑8.2% | 54↑12.4% | 48 | |
| Weighted Average Diluted Shares | 84↑12.5% | 75↑28.6% | 58↑8.2% | 54↑12.4% | 48 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.